SLXN — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-05-15

• Unless the context otherwise requires, references to “Silexion,” the “Company,” “we,” “us” and “our” in this MD&A generally refer to Silexion Therapeutics Corp, a Cayman Islands exempted company. For periods prior to the Business Combination, these terms refer to Silexion Israel, an Israeli company,…

• In September 2025, we furthermore entered into the ATM Agreement with H.C. Wainwright, as sales agent or principal, under which we may raise up to $13,170,000 on an ongoing basis via sales of our ordinary shares into the open market via an at-the-market financing mechanism (the “ATM”), which we plan…

• initiate a clinical trial powered for statistical significance with respect to SIL204;

• As described below, over the course of 2025, we underwent a hearings process with Nasdaq, which together with various remedial actions that we took (including financing transactions and a reverse share split), restored our compliance with Nasdaq listing rules related to shareholders’ equity and mini…

• As of March 31, 2026, our shareholders’ equity was below the requisite $2.5 million level totaled to $0.3 million. Nevertheless, as a result of our consummation of our May 2026 induced warrant exercise transaction in which we raised $1.0 million, and additional equity-increasing transactions effecte…

Text removed vs the prior filing · source: 10-Q · 2025-11-12

• Unless the context otherwise requires, references to the “Company,” “we,” “us” and “our” in this MD&A generally refer to: (i) for all periods preceding, and through the Closing of, the Business Combination, Silexion; and (ii) for all periods following the Closing, New Silexion.

• In September 2025, we furthermore entered into the ATM Agreement with H.C. Wainwright, as sales agent or principal, under which we may raise up to $13,170,000 on an ongoing basis via sales of our ordinary shares into the open market via an at-the-market financing mechanism (an “ATM”), which we plan …

• conduct toxicological studies with respect to SIL204 (which studies have been ongoing);

• initiate a clinical trial powered for statistical significance with respect to SIL204;

• As previously reported, on May 22, 2025, we received a delisting notice from the Nasdaq Listing Qualifications Department in respect of two listing deficiencies that we had been unable to remedy during the six-month cure period since we had initially been notified of those deficiencies, on November …

Text added vs the prior filing · source: 10-Q · 2026-05-15

• Our management evaluated, with the participation of our chief executive officer and chief financial officer, any change in our internal control over financial reporting that occurred during the fiscal quarter ended March 31, 2026 that has materially affected, or is reasonably likely to materially af…

• Based upon that evaluation, our chief executive officer and chief financial officer concluded that there was no change in our internal control over financial reporting during the fiscal quarter ended March 31, 2026 that has materially affected, or is reasonably likely to materially affect, our inter…

Text removed vs the prior filing · source: 10-Q · 2025-11-12

• During the fiscal quarter ended September 30, 2025, there was no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.